Intrommune Therapeutics

Intrommune Therapeutics, Inc. is a biotechnology company dedicated to developing safe and effective options for peanut and other food allergies. Headquartered in New York, NY, the company was founded in 2015. Intrommune is revolutionizing food allergy immunotherapies with a groundbreaking approach - delivering treatments during the daily habit of brushing teeth, ensuring consistent use. Their elegant new treatment platform for food allergies is anticipated to be safe, effective, and convenient. The company's first product focuses on providing therapy for patients suffering from peanut allergy, addressing a pressing need for the 32 million affected individuals in the U.S. Intrommune is shaping the future of food allergy treatment through the development of the oral mucosal immunotherapy (OMIT) platform. This innovation represents a long-term solution for the staggering 220 million individuals worldwide, with 32 million in the U.S., afflicted by this life-altering condition. Notably, the company recently received a major vote of confidence in the form of a Series B investment on 08 February 2022. The investors contributing to this milestone were not disclosed at the time of writing. Overall, Intrommune Therapeutics presents an intriguing investment opportunity with the potential to significantly impact the biotechnology and healthcare industries while addressing a prevalent global health concern.